Understanding the vascular injury pathway is crucial to developing rational strategies for secondary stroke prevention in children. The multicenter Vascular Effects of Infection in Pediatric Stroke (VIPS) cohort study will test the hypotheses that (1) infection can lead to childhood arterial ischemic stroke by causing vascular injury and (2) resultant arteriopathy and inflammatory markers predict recurrent stroke. The authors are prospectively enrolling 480 children (aged 1 month through 18 years) with arterial ischemic stroke and collecting extensive infectious histories, blood and serum samples (and cerebrospinal fluid, when clinically obtained), and standardized brain and cerebrovascular imaging studies. Laboratory assays include serologies (acute and convalescent) and molecular assays for herpesviruses and levels of inflammatory markers. Participants are followed prospectively for recurrent ischemic events (minimum of 1 year). The analyses will measure association between markers of infection and cerebral arteriopathy and will assess whether cerebral arteriopathy and inflammatory markers predict recurrent stroke.
Stroke is an increasingly recognized cause of childhood disability. 1 Population-based estimates of the annual incidence of childhood stroke range from 2.3 to 13 per 100 000 children. [2] [3] [4] [5] However, our current understanding of the pathogenesis of childhood arterial ischemic stroke is limited. Etiological factors have largely been derived from hospital series and case reports and include a wide range of disorders, from congenital heart disease to blood cancers to rare inborn errors of metabolism. [6] [7] [8] [9] Sickle cell disease and congenital heart disease have been emphasized in the literature and are likely strong risk factors for childhood arterial ischemic stroke. However, stroke is rarely the initial presentation of these diseases, and thus they are unlikely to explain the occurrence of arterial ischemic stroke in an otherwise healthy child. Instead, recent data suggest the importance of cerebral arteriopathies: as many as 64% of previously healthy children with a first arterial ischemic stroke have an arteriopathy of a cervical or intracranial vessel. 7 These arteriopathies also appear to be an important risk factor for recurrent stroke in these children. [10] [11] [12] Although childhood cerebral arteriopathies include established entities such as arterial dissection and moyamoya disease, most of these children have isolated unilateral focal stenosis of large intracranial arteries. This entity does not have features of spasm or dissection, and its occasional beaded and irregular appearance on angiogram suggests it represents a focal large-vessel vasculitis. 13, 14 Serial imaging often shows the lesions to be dynamic, indicating this focal stenosis is acquired, not congenital. 13 Although such imaging also suggests this arteriopathy rarely progresses after the initial 6 months (hence, this disorder has been called ''transient cerebral arteriopathy''), residual arterial lesions frequently persist. 10, 13 Infection has been implicated as an etiology of focal cerebral arteriopathy of childhood, and a focal vasculitis is the presumed underlying mechanism. Because of its known ability to invade vessel walls, possibly by direct spread from adjacent cranial nerves, varicella-zoster virus has received particular attention. 15 Multiple case reports describe a focal cerebral arteriopathy in children presenting with acute arterial ischemic stroke within weeks to months of chicken pox (primary varicella-zoster virus infection) or, less commonly, herpes zoster (secondary varicella-zoster virus infection) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ; varicellazoster IgG antibodies or DNA (by polymerase chain reaction) has been detected in the cerebrospinal fluid in a small number of these cases. 17, 18, 24 A varicella-zoster virus antigen-positive giant cell arteritis of the middle cerebral artery has been demonstrated pathologically in a fatal case of postvaricella stroke in a child (in addition to several fatal cases of postvaricella strokes in adults). [26] [27] [28] [29] A study of 70 childhood arterial ischemic stroke cases (with or without vascular abnormalities) found that the prevalence of chicken pox in the year before the stroke (31%) was higher than was the annual prevalence of chicken pox reported in the regional population (9%). 30 Last, in a case-control study that selected subjects with arterial ischemic stroke and an idiopathic focal arteriopathy and compared them with healthy controls, the association with varicella appeared strong (odds ratio [OR], 17.5; 95% confidence interval [CI], 2.8-117). 31 The term postvaricella arteriopathy has been coined for a focal cerebral arteriopathy in children with a history of varicella in the past 12 months. 32, 33 Other herpesviruses have also been implicated in the pathogenesis of childhood cerebral arteriopathies, although only in case reports: herpes simplex virus type 1 34 and Epstein-Barr virus, the latter confirmed by positive Epstein-Barr virus DNA in the cerebrospinal fluid. 35 Enterovirus has been implicated in an 18-month-old boy with focal stenosis of the proximal middle cerebral artery and enteroviral RNA in his cerebrospinal fluid. 36 Epidemiologic data from the International Pediatric Stroke Study (IPSS), an international registry of childhood ischemic stroke cases enrolled at 30 centers, also suggest that common childhood infections in general may play a role in the development of the arteriopathy seen in children with arterial ischemic stroke. Among 508 children enrolled with arterial ischemic stroke, a recent upper respiratory infection was noted in 9.1% of those with a cerebral arteriopathy, compared with 4.5% of those without an arteriopathy (OR, 2.1; P ¼ .048). 37 This association with upper respiratory infection was stronger for children with idiopathic arterial stenosis versus those with other arteriopathy (eg, arterial dissection, moyamoya) or no arteriopathy (OR, 2.8; P ¼ .003; 95% CI, 1.3-6.1).
Cerebral arteriopathies in children are of particular clinical significance in that they appear to confer an increased risk for recurrent stroke. In a California study, the overall 5-year cumulative recurrence rate was 19% (95% CI, 12%-30%) after an index stroke in a child (>28 days to 18 years of age). 10 Although there were no recurrences among children with normal vascular imaging, children with a stenosing vascular abnormality had a 5-year cumulative recurrence rate of 66% (P < .0001 for the comparison; 95% CI, 43%-87%). Similarly, in a German study, children whose strokes were classified as ''vascular'' in etiology had 4-fold odds of suffering a recurrence compared with children with idiopathic strokes. 34 A British group, on the other hand, did not find an association between arterial stenosis and recurrence, except in the setting of moyamoya, which is a progressive disease. 12 However, a persistent leukocytosis independently predicted recurrence (OR, 1.2; 95% CI, 1.04-1. 42 ), suggesting that chronic infection or inflammation may increase risk of recurrence.
To improve our understanding of the role of infection in the development of cerebral arteriopathies in children, we designed the Vascular Effects of Infection in Pediatric Stroke (VIPS) study to test the overall hypotheses that infection can lead to arterial ischemic stroke by causing vascular injury and that the resultant arteriopathy predisposes children to recurrent stroke. The specific aims are (1) to determine the association between infection and the arteriopathy observed in children with arterial ischemic stroke and establish the temporal nature of this relationship and (2) to prospectively determine whether arteriopathy and inflammatory markers predict stroke recurrence. A better understanding of the vascular injury pathway is crucial for our long-term goal of developing therapeutic interventions for secondary stroke prevention in children.
Methods

Overall Study Design
For aim 1, we are using a cross-sectional study design to determine the prevalence of infection and arteriopathy in children with an acute diagnosis of arterial ischemic stroke. Participants must be older than 28 days through 18 years of age and must be enrolled within 2 weeks of the stroke ictus. Study methods include chart review, parental interview, centralized imaging review, and collection of blood samples with centralized assays for biomarkers of infection. Testing for herpesviruses (varicella-zoster virus, herpes simplex virus type 1 and type 2, Epstein-Barr virus, and cytomegalovirus) will be performed in all cases. Additional biological samples (serum, plasma, DNA, and urine; and cerebrospinal fluid, if obtained for clinical purposes) will be aliquoted and banked to create a repository for future studies, which will further explore the associations between infection, inflammation, and arteriopathy. For aim 2, we are performing a prospective cohort study using the childhood arterial ischemic stroke cases identified for aim 1. We are following these subjects prospectively for the duration of the study period but for a minimum of 1 year.
Setting
The VIPS has built on the existing infrastructure of the International Pediatric Stroke Society (IPSS). The Hospital for Sick Children (University of Toronto), which directs the IPSS, serves as the VIPS Network Coordinating Center and Data Core, expanding current IPSS databases and Web-based data entry systems to accommodate VIPS-specific clinical, radiographic, and laboratory assay data. The University of California San Francisco serves as the VIPS Study Coordinating Center, Imaging Core, and Biostatistics Core.
The Center for Advanced Laboratory Medicine at Columbia University serves as the VIPS Laboratory Core.
The VIPS has 34 sites as of January 1, 2011: 17 in the United States, 7 in Canada, and 1 site each in Argentina, Australia, Chile, China, Germany, Hong Kong, Malaysia, Philippines, Serbia, and the United Kingdom (see Appendix). All have met the following site selection criteria: basic laboratory capabilities necessary for processing biological specimens; access to a refrigerated centrifuge, À70 C freezer, and dry ice (an exception was made for a small number of centers, which will be allowed to send samples on cold packs); an MRI scanner with a minimum magnet strength of 1.5 T; ability to perform a minimum neuroimaging protocol, including brain MRI and brain vascular imaging, as part of their routine clinical care; MRI slice thickness of 5 mm or less; and ability to provide DICOM-formatted data burned onto a CD or DVD. Our decision to use only clinically obtained imaging was both financial and ethical in that it circumvents the potential risks of sedation in children who would require anesthesia for their research scans.
Inclusion and Exclusion Criteria
Potential cases are identified primarily through the clinical practice of the IPSS coinvestigators who are considered the pediatric stroke experts at their respective institutions and are thereby made aware of acute pediatric stroke cases. In addition, coinvestigators advertise the study to their colleagues in child neurology, hematology, and pediatric critical care. Inclusion criteria are (1) acute arterial ischemic stroke (using the clinical and radiographic criteria defined below) within 2 weeks of enrollment, (2) age >28 days and <19 years at the time of the stroke ictus, and (3) parental consent. Cases will be excluded if (1) there is no parent or guardian available for interview, or (2) the minimum neuroimaging protocol, defined below, was not performed. Because we are interested in the association between infection and arteriopathy in all cases, even among children otherwise predisposed to stroke, we include children with known stroke risk factors, such as sickle cell disease, congenital heart disease, and moyamoya.
Cases are initially confirmed by the local coinvestigator using clinical and radiographic diagnostic criteria for stroke: (1) clinical, a focal neurological deficit of acute onset or a seizure; (2) radiographic, a CT or MRI showing a focal brain infarct conforming to an established arterial territory in a location and of a maturity consistent with the neurological signs and symptoms. They are then subjected to a centralized review and case confirmation process, described below.
Medical Records Abstraction
Data regarding the index arterial ischemic stroke are obtained through review of medical records by the local coinvestigator and abstracted onto the case report forms. These data include neurologic presentation of the stroke; past medical history, with particular attention to perceived risk factors for childhood stroke [6] [7] [8] [9] ; and etiologic workup (diagnostic studies performed to identify etiology of the stroke). The case report forms include details regarding serious acute infections such as bacteremia/sepsis, meningitis, or encephalitis.
Parent/Surrogate Interview
The site investigator or project coordinator performs a standardized interview of the parents/guardians of each enrolled subject as soon as possible and at most within 1 week of enrollment (maximum of 3 weeks after stroke ictus). Data obtained from the interview include presence or absence of recent infection, recent febrile infection, or prior chicken pox; type of infection (eg, upper respiratory versus urinary tract infection); and infectious symptoms (such as cough, vomiting, diarrhea, etc). In addition, we ask the date of the most recent episode of each specific type of infection in that child's life. As a measure of infectious burden, we ask parents to estimate the number of infections, duration of infections, and missed school/preschool/daycare due to infection in the 6-month interval preceding stroke. Additional interview questions pertain to gender, age, self-reported ethnicity, indicators of socioeconomic status (most advanced level of parental education and household income), vaccination history, and family history of stroke at a young age. Questions also include ''distracter variables'' to assess for potential recall bias. For example, we ask whether the subjects have a remote history of urinary tract infections, abnormal head shape, and umbilical hernias in the neonatal period.
Definitions/Diagnostic Criteria for Infection
Recent infection (the primary exposure variable) is defined as parental recall of any infection within 4 weeks preceding the stroke ictus date, exclusive of central nervous system infections (meningitis/ encephalitis), bacteremia/sepsis, or chicken pox (infections with distinct mechanisms for causing arterial ischemic stroke that will therefore be considered separately). This includes any one of the following subtypes (further defined below): upper respiratory infection, pneumonia, acute otitis media, sinusitis, and acute gastroenteritis. Because the association between infection and stroke in adult studies was strongest for febrile infections 38, 39 and because infectious symptoms (such as cough and nasal discharge) can mimic allergic symptoms and are relatively ubiquitous in young children, we are also measuring recent febrile infection, defined as parental report of a temperature greater than 38 C (100.4 F) that was attributed to an infectious etiology within 4 weeks preceding the stroke ictus. Upper respiratory infection is defined as respiratory symptoms (cough, rhinorrhea, sore throat) attributed by the parents to an infectious etiology. Similarly, acute gastroenteritis will be defined as 2 of 3 symptoms of vomiting, diarrhea, or fever, attributed by the parents to an infectious etiology. Acute otitis media, pneumonia, and sinusitis will be defined as parental report of a physician diagnosis of those illnesses.
We define central nervous system infections as meningitis or encephalitis within 4 weeks of the stroke ictus/index date. These diagnoses will require supportive documentation in the medical records, in addition to parental report. A diagnosis of bacteremia/sepsis will be based on positive blood culture results. Criteria for the diagnosis of meningitis/encephalitis will include a physician diagnosis and a cerebrospinal fluid profile supporting the diagnosis (elevated leukocyte count and protein). Prior chicken pox will be defined by parental report alone because this has been shown to be specific for the diagnosis and because a physician diagnosis often is not made as children with a suspected diagnosis are discouraged from coming to clinic (to prevent spread to other children). 40 The time interval we selected for the definition of recent infection is arbitrary, based only on prior literature using a similar cutoff. 38, 41 However, the strength of the association between infection and stroke may vary by the temporal proximity of the infection. Therefore, in addition to defining recent infection, recent febrile infection, and the infectious subtypes as dichotomous variables (yes/no) within defined time frames, we will ask the parents to estimate the date of onset of the most recent infection. This will allow us to evaluate time-dependent associations over a range of possible times.
We define infectious burden based on parental report in 3 ways: (1) the estimated total number of infectious illnesses in the past 6 months, (2) the estimated total number of days of infectious illness in the past 6 months (a reflection of both frequency and duration of illness), and (3) the estimated total number of days of missed school/preschool/daycare due to infectious illness. A fourth measure of infectious burden will be the sum of positive testing for herpesviruses: positive herpes serologies or positive polymerase chain reaction, suggestive of either acute or remote infection. This will be a categorical variable ranging from 0 (all herpesvirus testing negative) to 5 (evidence of either acute or remote infection with all 5 herpesviruses tested for in this study).
Neuroimaging review. The purpose of centralized imaging review is (1) to confirm the index diagnosis of arterial ischemic stroke, as described above; (2) to describe and categorize vascular findings; and (3) to confirm recurrent arterial ischemic stroke. The imaging studies subjected to review include (1) baseline brain MRI studies, (2) baseline vascular imaging studies (MR angiography, CT angiography, and/or conventional angiography), (3) all follow-up vascular imaging studies in children with abnormal baseline vascular imaging, and (4) follow-up brain MRI (or CT) studies performed for suspected recurrent stroke. At most IPSS centers, follow-up vascular imaging is routinely performed on all children with abnormalities on baseline vascular imaging; it will be used to aid in the classification of the arteriopathies (as their evolution can help distinguish different subtypes) and to assess their natural history. Follow-up brain MRI is routinely performed on all children with clinical symptoms of recurrent stroke and will be used for the confirmation of recurrences for specific aim 2.
The minimum neuroimaging protocol for subject inclusion in the study will consist of the following MRI sequences: axial T2weighted images, axial diffusion-weighted images, axial or coronal fluid-attenuated inversion recovery images, and time of flight magnetic resonance angiography of the brain. Magnetic resonance angiography of the neck and axial or coronal gradient echo images of the brain are strongly recommended. Conventional angiography and CT angiography will be accepted in lieu of MR angiography, although all VIPS sites have indicated that MR angiography is their first-line vascular imaging study.
Centralized radiology review is performed by 2 study neuroradiologists (MW and CLS), with adjudication by a third (AJB). Disputes are resolved by discussion and consensus among the 3 radiologists. The radiologists abstract data regarding approximate infarct size, location, and acuity and any associated hemorrhage. In their vascular interpretation, because diagnostic criteria for vascular abnormalities in children are not firmly established, they will primarily classify the vascular imaging as normal or abnormal and then completely describe vascular findings. They will also categorize them based on prevalence using the definitions for arteriopathy described below. We will reassess these definitions after the first 50 sets of imaging studies are reviewed. If we feel that a useful vascular classification system can be developed, we will create specific definitions for the categories and then re-review the vascular imaging with independent classification by the 2 primary reviewers and adjudication by the third. We will then calculate interobserver reliability.
Definitions/Diagnostic Criteria for Arteriopathy
We define arteriopathy as any stenosing abnormality of a cervical or intracranial artery, which is further subcategorized into small/ medium-versus large-vessel disease. 10 Because complete vessel occlusion may represent thrombus rather than an underlying vascular abnormality, isolated occlusion will be classified separately. Because the label ''transient cerebral arteriopathy'' can, by definition, only be applied to subjects with follow-up vascular imaging (demonstrating nonprogression after 6 months), we chose to use the more inclusive label that can be applied to baseline imaging: focal cerebral arteriopathy of childhood. 37 This is defined as a unilateral focal stenosis of 1 or multiple adjacent segments of the large vessels of the circle of Willis (the vessels typically involved in transient cerebral arteriopathy, such as the distal internal carotid or proximal middle or anterior cerebral arteries), in the absence of diagnostic features of arterial dissection or moyamoya. Within the category of focal cerebral arteriopathy of childhood, we also define the subgroup of transient cerebral arteriopathy: features of focal cerebral arteriopathy of childhood on baseline imaging that show the typical evolution of transient cerebral arteriopathy on follow-up imaging (eg, ''banding'' or ''beading'' of the vessel at baseline progressing to smooth stenosis). 13, 32 Arterial dissection will be defined by a focal irregular stenosis of a large vessel in the presence of a double lumen, intimal flap, or pseudoaneurysm. 11, 32, 42 Moyamoya will be defined as bilateral stenosis or occlusion of the distal internal carotid or proximal middle cerebral or anterior cerebral arteries and abnormal collateral vascular networks in the vicinity of the stenosis/occlusion (the so-called moyamoya vessels). 43 This designation will include both the primary (idiopathic) form and secondary disease (eg, in the setting of sickle cell disease or genetic syndromes such as Down syndrome). Diffuse cerebral vasculitis will be defined as multifocal areas of segmental narrowing and dilatation (beading) involving small or medium vessels. 44, 45 We recognize that the focal cerebral arteriopathy of childhood category, as currently defined, may be heterogeneous and could include cases of arterial dissection without diagnostic imaging features, early (unilateral) moyamoya, and large-vessel vasculitis. However, this category represents both the most prevalent group of described vascular abnormalities in children with arterial ischemic stroke and the least well understood. Our strategy is to err toward overinclusivity in this category, selecting out only the well-defined arteriopathies. We can then use the data obtained in this study to better understand this group and devise a rational scheme for further subcategorization.
Ascertainment of Recurrences
We anticipate that in the event of a recurrence, most children will be readmitted to the same hospital where they were initially enrolled, and the local investigator (as the resident childhood stroke expert) will be notified of their admission on a clinical basis. Although a referral bias could exist if first stroke cases are referred to a tertiary center (VIPS enrolling site) but then re-present to their initial hospital only, we suspect this is unlikely; recurrent strokes in children are typically a source of great concern and are probably more likely to result in a re-referral to the regional tertiary center. Regardless, the site investigator or project coordinator will also perform phone follow-up every 4 months and at the completion of the study follow-up period to inquire about recurrent strokes. In addition, investigators will perform quarterly reviews of the cases' medical records to identify any readmissions, urgent care visits, or follow-up head imaging suggestive of a recurrence.
Confirmation of Recurrences
Recurrences will be initially confirmed by the local coinvestigator using the same clinical and radiographic criteria used for the index stroke, with the added criterion of radiographic evidence of new infarction. They will then be subjected to a centralized adjudication process. Similar to the adjudication process for the initial case confirmation, the imaging and clinical history will be independently reviewed by a study neuroradiologist (MW) and pediatric stroke neurologist (HJF), with adjudication of disagreements by a third investigator (AJB). Transient ischemic attacks will be excluded from the definition of recurrence out of concern for observer bias: the decision as to whether focal symptoms represent a transient ischemic attack may be affected by the treating physician's knowledge of the case's exposure status (presence or absence of arteriopathy). Silent infarctions (seen on imaging but with no clinical correlation) will be noted but not included as an outcome due to incomplete ascertainment (follow-up brain imaging will not be performed in all subjects).
Biologic Sample Collection/Handling/Storage
We are collecting approximately 16 mL of blood at the time of enrollment (10 mL for serum and 6 mL for plasma in ethylenediaminetetraacetic acid or a maximum of 3 mL/kg in a 6-week period; exact volumes vary slightly by individual site institutional review board requirements). If needed, blood may be drawn on separate successive days to comply with site-specific institutional review board-approved algorithms for pediatric phlebotomy. Convalescent serum and plasma samples are collected 7 to 28 days after the initial sample collection. We anticipate that convalescent samples will not be available for 10% of participants. In addition, we will collect 10 mL of urine from willing participants and 5 mL of research cerebrospinal fluid when lumbar puncture is performed for clinical indications. Blood samples are centrifuged, aliquoted, and frozen at -70 C at the enrolling site. Samples are shipped up to twice yearly on dry ice to the Center for Advanced Laboratory Medicine for storage and batched analysis. Samples will be analyzed for herpesvirus serologies and polymerase chain reaction and for inflammatory markers. The remaining samples, including buffy coat specimens to be used for potential future genetic testing, will be stored and curated in a repository at the Center for Advanced Laboratory Medicine.
Assays for Herpesviruses
Herpesviruses are the group of pathogens that has been most frequently implicated in the pathogenesis of vascular injury. As discussed above, varicella-zoster virus, herpes simples virus, and Epstein-Barr virus have been implicated in reports of arteriopathy in children. Varicella-zoster virus, cytomegalovirus, and herpes simplex virus have also been implicated in the pathogenesis of atherosclerosis in adults. 46 We will perform serological assays for varicella-zoster virus, herpes simplex virus, cytomegalovirus, and Epstein-Barr virus at the Center for Advanced Laboratory Medicine; the specific testing we will perform for each virus is shown in Table 1. Serologies will be performed using an automated immunochemiluminescent assay (Immulite, Diagnostic Products Corporation, Los Angeles, California). This is a solid-phase, 2-step enzyme-labeled immunoassay very similar to a standard enzyme-linked immunosorbent assay. It uses beads coated with viral antigen and a chemiluminescent substrate for signal. Assays on this system for serologies for herpes simplex virus type 1, herpes simplex virus type 2, and cytomegalovirus are standardized and FDA-approved. The system requires 20 mL of serum for each of the tests. The assays have been validated in the Center for Advanced Laboratory Medicine laboratory. On the acute samples, we will perform IgG and IgM serologies and plasma polymerase chain reaction (except for cytomegalovirus, as the significance of a positive plasma cytomegalovirus polymerase chain reaction is less certain). On convalescent samples, we will repeat IgM and IgG serologies. In addition, we will study all available cerebrospinal fluid samples with viral polymerase chain reaction and intrathecal antibodies for herpes simplex virus and varicella-zoster virus. For the cross-sectional analysis, the presence or absence of acute herpesvirus infection and remote herpesvirus infection (used for our definition of infectious burden) will be determined through independent review of all available data by 2 pediatric infectious disease specialists (CG and a clinical infectious disease fellow), with adjudication of disputes by a third investigator (MSVE). Data subject to review will include clinical history (including history of varicella vaccination or clinical infection), timing of the sample collections, and acute and convalescent serology results.
Assays for Inflammatory Markers
The rationale for our choice of inflammatory markers is shown in Table 2 ; these markers have been shown to predict recurrent stroke and cardiovascular events in adults, and we will determine whether a similar association exists for childhood arterial ischemic stroke. We will measure C-reactive protein, serum amyloid A, myeloperoxidase, and lipoprotein-associated phospholipase A2 on all samples, as well as tissue necrosis factor-alpha on that majority of samples that are frozen and shipped on dry ice. Assays for C-reactive protein and serum amyloid A will be performed using the Dade-Behring BN-II nephelometer (Dade-Behring, Deerfield, Illinois). The nephelometric method to measure C-reactive protein has become recognized as the national standard assay for this marker. Assays for myeloperoxidase, tissue necrosis factor-alpha, and lipoprotein-associated phospholipase A2 will be performed using commercially available enzyme-linked immunosorbent assay kits (Biosource International, Camarillo, California, and diaDexus, Inc, South San Francisco, California). A research technician blinded to subject outcome status will perform all assays.
Statistical Analysis Plan Sample Size
We chose our sample size of 480 subjects based on power calculations for the primary association of interest, that between recent infection (within 4 weeks of the stroke ictus) and focal cerebral arteriopathy of childhood. In a retrospective population-based cohort study of childhood stroke based in Northern California, 47 the proportion of children with arterial ischemic stroke who had an urgent care visit for an infectious illness in the 4 weeks preceding the stroke was 27% (95% CI, 18%-37%, unpublished preliminary data). The proportion of children with an idiopathic stenosis was 27% (95% CI, 16%-41%) in the Californian cohort 10 and 23% (95% CI, 19%-27%) in the IPSS registry. 37 The point estimate for the OR for the association between infection (variously defined) and stenosing arteriopathy was 2.3 in the Californian cohort and 2.4 in the IPSS registry. 37 Assuming a 25% prevalence of recent infection and a 20% prevalence of idiopathic stenosis in the unexposed group, we would need 480 cases to have 80% power to detect an OR of 2.0 (alpha set at .05).
Aim 1
In a cross-sectional analysis, we will measure the association between the primary predictor (recent infection, as ascertained from the parental interview) and the outcome (focal cerebral arteriopathy of childhood) using logistic regression; ORs and exact CIs will be calculated. We will first perform a univariate analysis. We will assess potential confounders (such as age, gender, and ethnicity) by determining whether they are associated with the predictor and outcome. Then, to determine whether recent infection is an independent risk factor for focal cerebral arteriopathy of childhood, multivariate logistic regression models will be constructed and will include potential confounders. Potential effect modifiers (such as race/ethnicity and geographic location) will be assessed through stratification and tests for interaction adding cross-product variables to the model. Secondary predictors (recent febrile infection, recent herpesvirus infection, infectious burden) will be analyzed in a similar fashion. For categorical variables, we will use chisquare tests to compare proportions, or Fisher's exact test when necessary. For continuous variables, we will employ Student's t tests. We will create additional logistic regression models to determine which of these variables are independent predictors of focal cerebral arteriopathy of childhood. Because our primary analysis will include all cases, the reference group (children without focal cerebral arteriopathy of childhood) will be heterogeneous, including children with no arteriopathy and children with other forms of arteriopathy (such as dissection and moyamoya). As a secondary analysis, we will repeat the above analyses, excluding children with other forms of arteriopathy. In addition, because of literature suggesting an association between recent infection and arterial dissection in adults, 48, 49 we will analyze the association between recent infection and other arteriopathy subtypes, including dissection.
We will perform additional analyses to assess potential recall bias in our primary analysis by comparing (1) the proportion of positive responses to ''distracter variables'' and (2) the proportion of reported varicella-zoster infection validated by biologic assay, accounting for prior varicella vaccination, in children with and without focal cerebral arteriopathy of childhood.
We acknowledge that the cutoff of 4 weeks in our definition of recent infection is somewhat arbitrary, derived from prior literature on infection and stroke in adults. Hence, we will explore the relationship between time since most recent infection (to the stroke ictus) and probability of focal cerebral arteriopathy of childhood. Because this relationship is unlikely to be linear, we will use regression splines. 50 This technique fits a regression line that is continuous at specified cut points and linear in the intervals between those cut points. This allows the predictor variable (time) to be treated as continuous, despite the nonlinear relationship. We will also assess for seasonal variation by determining whether stroke in cases with focal cerebral arteriopathy of childhood clusters in different seasons than in cases without.
Aim 2 Analysis
The associations between the primary predictor (arteriopathy) and the outcome (time from initial stroke to recurrent ischemic stroke) will be assessed with survival analyses. Cases will be censored at the date of death or their last contact (telephone or in-person) prior to the end of the study, whichever comes first. For univariate analyses, Kaplan-Meier curves will be constructed, and log-rank tests will be performed to test the significance of the difference between dichotomous predictors. Univariate Cox proportional hazards models will be used to determine hazard ratios as a measure of relative risk. To determine whether arteriopathy is an independent risk factor for recurrent arterial ischemic stroke, multivariate Cox proportional hazards models will be constructed and will include potential confounders such as gender, ethnicity, and markers of socioeconomic status. To determine whether the association between arteriopathy and recurrence varies by arteriopathy subtype (arterial dissection, moyamoya, focal cerebral arteriopathy of childhood), we will perform stratified survival analyses. To determine whether a history of recent infection (prior to the index stroke) modifies the association, we will perform stratified analyses and enter a cross-product variable into the Cox proportional hazards models to test for interaction. We will perform additional analyses to determine whether levels of inflammatory markers predict recurrence. As these levels will be continuous, we will convert them to categorical variables by dividing them into quartiles. We will then employ the same survival analysis techniques to determine whether a higher level predicts recurrence. We will create multivariate Cox proportional hazards models to adjust for potential confounders, including infarct size, stroke severity, and concurrent poststroke hospitalacquired infections (although uncommon in children).
Discussion
We describe the design of the first prospective multicenter study to assess the relationship between childhood infections and the cerebral arteriopathy commonly observed in previously healthy children presenting with a first arterial ischemic stroke. As a secondary aim, the VIPS study will prospectively establish the rate of recurrent arterial ischemic stroke in children and determine whether inflammatory markers and abnormalities on vascular imaging predict recurrence. Studies of childhood arterial ischemic stroke have long been challenged by the relative rarity of this disease, making it difficult for any single center or small collaborative effort to achieve a powerful sample size. The VIPS study overcomes that hurdle by using and building on the existing infrastructure of the IPSS, an international effort that has enrolled more than 2500 neonatal and childhood stroke patients since 2003. Our primary predictor, recent infection, will be ascertained by parental interview. The major limitations of this approach are recall bias and inability to detect subclinical infections. However, we will manage recall bias by (1) minimizing such bias by performing interviews within a discrete interval from the stroke ictus and (2) measuring residual recall bias through distractor variables. In addition, we will secondarily measure infection through biologic assays for herpesviruses, the class of viruses most implicated as mediators of vascular injury. This measure will be both resistant to recall bias and sensitive to subclinical infections.
Our primary outcome, focal cerebral arteriopathy, will be ascertained through centralized review of vascular imaging studies. Our study takes advantage of clinically obtained brain and vascular imaging. This approach decreases the cost of the study and circumvents ethical issues around subjecting children to the risk of anesthesia to perform imaging studies for research purposes. However, a clear disadvantage is the variability of the imaging studies that will be obtained in VIPS. As we designed the minimum imaging protocol, we tried to maximize the standardization of the imaging studies across centers without excluding smaller institutions through overly rigorous criteria that would decrease the generalizability of our results.
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Predictive of stroke in several adult populations. 76, 77 Predictive of recurrent stroke and other vascular events in the NOMAS population (see preliminary data). 63 CRP, C-reactive protein; HsCRP, high sensitivity C-reactive protein; IL, interleukin; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial infarction; MPO, myeloperoxidase; NOMAS, Northern Manhattan Study; TIA, transient ischemic attack; TNF, tumor necrosis factor. study. 51 Hence, the arteriopathy that we call focal cerebral arteriopathy of childhood in this study will likely still represent a variety of etiologies, including a focal arteritis, intracranial dissection, and even early moyamoya. Ultimately, better imaging techniques, such as arterial wall imaging for intramural inflammation or blood products, 52 will be needed to better define the arteriopathies observed in children. Despite these limitations, the VIPS study will provide useful evidence regarding the role of infection in the development of cerebral arteriopathies in children and rates and predictors of recurrent stroke. This information will be crucial for the development of secondary stroke prevention strategies in children. In addition, VIPS will provide a valuable library of clinical information and imaging, with a corresponding repository of DNA and other biological samples, which will allow the testing of additional hypotheses to further our understanding of childhood stroke.
